Skip to content
B
BiotechEdge

Biotech M&A Tracker

Which biotech stocks were acquisition targets — and which specialist hedge funds were already positioned before the deal?

21
Deals Tracked
$174B+
Total Value
5
Pending
16
Closed
TargetAcquirerDeal ValueStatusFunds HeldAnnounced
$SLNOSoleno TherapeuticsNeurocrine Biosciences$2.9Bpending8Apr 2026
$CNTACentessa PharmaceuticalsEli Lilly$7.8Bpending10Mar 2026
$APLSApellis PharmaceuticalsBiogen$5.6Bpending6Mar 2026
$ACLXArcellxGilead Sciences$7.8Bpending4Feb 2026
$FOLDAmicus TherapeuticsBioMarin$4.8Bpending5Jan 2026
$DVAXDynavax TechnologiesSanofi$1.8Bclosed3Dec 2025
$RNAAvidity BiosciencesNovartis$12.0Bclosed10Oct 2025
$AKROAkero TherapeuticsNovo Nordisk$4.7Bclosed9Oct 2025
$ETNB89bioRoche$3.5Bclosed5Sep 2025
$ITOSiTeos TherapeuticsConcentra Biosciences$236Mclosed4Jul 2025
$VRNAVerona PharmaMerck$10.0Bclosed6Jul 2025
$IGMSIGM BiosciencesConcentra Biosciences$83Mclosed2Jul 2025
$VERVVerve TherapeuticsEli Lilly$1.3Bclosed5Jun 2025
$BPMCBlueprint MedicinesSanofi$9.1Bclosed6Jun 2025
$SWTXSpringWorks TherapeuticsMerck KGaA$3.4Bclosed1Mar 2025
$ITCIIntra-Cellular TherapiesJohnson & Johnson$14.6Bclosed2Jan 2025
$ACCDAccoladeTranscarent$621Mclosed1Jan 2025
$CERECerevel TherapeuticsAbbVie$8.7BclosedDec 2023
$CBAYCymaBay TherapeuticsGilead Sciences$4.4Bclosed1Oct 2023
$SGENSeagenPfizer$43.0BclosedMar 2023
$HZNPHorizon TherapeuticsAmgen$27.8BclosedDec 2022

How This Works

Every quarter, large investment managers file SEC Form 13F disclosing their holdings. We track 20 specialist biotech hedge funds and cross-reference their positions against M&A activity. When a company they held gets acquired, it shows up here.

The Funds column shows how many of our tracked funds held the target. Click any deal for the full breakdown — position sizes, entry dates, and whether the fund was still holding at announcement.